Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

The Centers for Disease Control and Prevention recommend adjunctive antitoxins when systemic anthrax is suspected. Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax in combination with antibiotics and for prophylaxis when alternat...

Full description

Bibliographic Details
Main Authors: Yamamoto, Brent J., Shadiack, Annette M., Carpenter, Sarah, Sanford, Daniel, Henning, Lisa N., Gonzales, Nestor, O'Connor, Edward, Casey, Leslie S., Serbina, Natalya V.
Format: Online
Language:English
Published: American Society for Microbiology 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038297/

Similar Items

Similar Items